Eisai (ESALY) Posts Earnings Results

Eisai (OTCMKTS:ESALY) posted its earnings results on Friday. The company reported $0.29 EPS for the quarter, Morningstar.com reports. The company had revenue of $1.37 billion for the quarter. Eisai had a return on equity of 4.96% and a net margin of 5.50%.

Eisai (ESALY) traded down $1.23 during trading hours on Friday, hitting $56.84. The company had a trading volume of 2,542 shares, compared to its average volume of 2,258. The company has a quick ratio of 1.81, a current ratio of 2.18 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $17,218.68, a P/E ratio of 59.20 and a beta of -0.28. Eisai has a 12 month low of $50.31 and a 12 month high of $63.06.

Separately, Zacks Investment Research downgraded Eisai from a “hold” rating to a “sell” rating in a research report on Friday, October 27th.

WARNING: “Eisai (ESALY) Posts Earnings Results” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/03/eisai-esaly-posts-earnings-results.html.

Eisai Company Profile

Eisai Co, Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company’s businesses include pharmaceutical business and other business. The Company’s segments include Japan (Prescription Medicines, Generics and Diagnostics), Americas (North America, Central and South America), China, Asia (South Korea, Taiwan, Hong Kong, India and ASEAN), EMEA (Europe, the Middle East, Africa and Oceania) and Consumer Healthcare Business-Japan.

Earnings History for Eisai (OTCMKTS:ESALY)

Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply